Tobetsa mona ho bonts'a lifolakha tsa HAO leqepheng lena mme u lefelle katleho feela

Litaba tsa mohala

Kalafo ea Pele e Ananetsoe ho EU ho Lebela Sesosa sa Sickle Cell Disease

ngotsoeng ke mohlophisi

Brand Institute e phatlalalitse tšebelisano ea eona e atlehileng le Global Blood Therapeutics (GBT) ka ho reha kalafo ea bona e amohetsoeng ke EMA, OXBRYTA, e bontšitsoeng bakeng sa kalafo ea phokolo ea mali ea haemolytic ka lebaka la lefu la cell cell (SCD) ho bakuli ba baholo le bana ba lilemo tse 12 le ho feta. monotherapy kapa hammoho le hydroxycarbamide (hydroxyurea). Sena se latela tumello ea FDA le Health Canada ea kalafo ka 2019.              

"Sehlopha sohle sa Brand Institute le Setsi sa Tšireletso ea Lithethefatsi se thoholetsa Global Blood Therapeutics ka tumello ea FDA ea OXBRYTA," ho boletse Molula-setulo le CEO oa Brand Institute, James L. Dettore. "Kalafo ena e fetolang e na le monyetla oa ho etsa phapang e kholo ho ba Europe ba phelang le lefu lena le fokolisang."

OXBRYTA ke moriana oa pele o amohetsoeng Europe o thibelang ka ho toba checkle hemoglobin (HbS) polymerization, motheo oa molek'hule oa ho kula le ho timetsoa ha lisele tse khubelu tsa mali ho SCD. OXBRYTA e sebetsa ka ho eketsa kamano ea hemoglobin le oksijene. Kaha hemoglobin e nang le oksijene ea sekele ha e pomeletse, OXBRYTA e thibela sekele ea hemoglobin polymerization le phello ea ho kula le ho senyeha ha lisele tse khubelu tsa mali.

"Re lumela hore lebitso la lebitso la OXBRYTA le loketse sehlahisoa," Dettore a tsoela pele. "Ho ekelletsa ho sehlomathiso se amanang le 'oksijene', se supang tšebetso ea sehlahisoa, lebitso lena le na le litšobotsi le litšoaneleho tse ngata tseo re li phehellang ha re theha lebitso le lecha la lets'oao la meriana."

Litaba Tse Amanang

Mabapi le mongoli

mohlophisi

Mohlophisi e moholo oa eTurboNew ke Linda Hohnholz. O lula ntlong e kholo ea eTN e Honolulu, Hawaii.

Leave a Comment

Arolelana ho...